Ticagrelor safe after fibrinolysis – and now there’s a reversal agent

Ticagrelor represents a safe treatment option after fibrinolysis for ST-elevation myocardial infarction (STEMI), with 12-month results from the TREAT study showing it was noninferior to clopidogrel. The primary endpoint (major bleeding at 30 days) was previously reported in 2018 showing comparable...

Ticagrelor represents a safe treatment option after fibrinolysis for ST-elevation myocardial infarction (STEMI), with 12-month results from the TREAT study...

Medicopolitical news

AMA calls for immediate end to Medicare freeze on pathology rebates

The AMA has called on the Federal government to immediately end the freeze on Medicare rebates for pathology services that has been in place for more than 20 years. Federal AMA president Dr Tony Bartone made the call in response to an announcement...

The AMA has called on the Federal government to immediately end the freeze on Medicare rebates for pathology services that has been...

Blood cancers

Challenges amid new promise in AML

The treatment landscape for acute myeloid leukaemia (AML) - and hopefully patient outcomes - are expected to change significantly over the next couple of years. Haematologist Associate Professor Andrew Wei, from Monash University and head of leukaemia research at The Alfred Hospital,...

The treatment landscape for acute myeloid leukaemia (AML) - and hopefully patient outcomes - are expected to change significantly over...

Bleeding disorders

Treatment-free response possible in ITP kids after romiplostim

Romiplostim is effective in boosting platelet counts in most children with chronic immune thrombocytopenia (ITP) and can lead to a treatment-free response in almost a quarter of children. A long-term extension study enrolled 66 children from previous phase 1/2 and...

Romiplostim is effective in boosting platelet counts in most children with chronic immune thrombocytopenia (ITP) and can lead to a...